MLN-8237
Description In vitro In vivo- Product Name
- MLN-8237
- CAS No.
- 1028486-01-2
- Chemical Name
- MLN-8237
- Synonyms
- Alisertib;Alisertib (MLN8237);MLN8237 (Alisertib);CS-277;MLN-823;MLN-8237;MLN-8237; MLN 8237;MLN-8237 USP/EP/BP;13C,2H3]-Alisertib;ALIERTIB (MLN 8237)
- CBNumber
- CB62510095
- Molecular Formula
- C27H20ClFN4O4
- Formula Weight
- 518.92
- MOL File
- 1028486-01-2.mol
MLN-8237 Property
- Boiling point:
- 729.1±70.0 °C(Predicted)
- Density
- 1.43±0.1 g/cm3(Predicted)
- storage temp.
- -20°C
- solubility
- Soluble in DMSO (up to 5 mg/ml)
- form
- solid
- pka
- 4.07±0.10(Predicted)
- color
- Off-white
- Stability:
- Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
N-Bromosuccinimide Price
- Product number
- 13602
- Product name
- MLN8237
- Purity
- ≥98%
- Packaging
- 1mg
- Price
- $32
- Updated
- 2024/03/01
- Product number
- 13602
- Product name
- MLN8237
- Purity
- ≥98%
- Packaging
- 5mg
- Price
- $131
- Updated
- 2024/03/01
- Product number
- 13602
- Product name
- MLN8237
- Purity
- ≥98%
- Packaging
- 10mg
- Price
- $230
- Updated
- 2024/03/01
- Product number
- 017705
- Product name
- MLN 8237
- Packaging
- 5mg
- Price
- $496
- Updated
- 2021/12/16
- Product number
- A4110
- Product name
- MLN8237(Alisertib)
- Packaging
- 1unit
- Price
- $28
- Updated
- 2021/12/16
MLN-8237 Chemical Properties,Usage,Production
Description
Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.
In vitro
MLN8237 shows >200-fold higher selectivity for Aurora A than the structurally related Aurora B with an IC50 of 396.5 nM, and does not have any significant activity against 205 other kinases. [1] MLN8237 (0.5 μM) treatment inhibits the phosphorylation of Aurora A in MM1.S and OPM1 cells, without affecting the Aurora B mediated histone H3 phosphorylation. MLN8237 significantly inhibits cell proliferation in multiple myeloma (MM) cell lines with IC50 values of 0.003-1.71 μM. MLN8237 displays more potent anti-proliferation activity against primary MM cells and MM cell lines in the presence of BM stroma cells, as well as IL-6 and IGF-1 than against MM cells alone. MLN8237 (0.5 μM) induces 2- to 6-fold increase in G2/M phase in primary MM cells and cell lines, as well as significant apoptosis and senescence, involving the up-regulation of p53, p21 and p27, as well as PARP, caspase 3, and caspase 9 cleavage. In addition, MLN8237 shows strong synergistic anti-MM effect with dexamethasone, as well as additive effect with doxorubicin and bortezomib.MLN8237 (0.5 μM) treatment causes the inhibition of colony formation of FLO-1, OE19, and OE33 esophageal adenocarinoma cell lines, and induces a significant increase in the percentage of polyploid cells, and subsequently an increase in the percentage of cells in the sub-G1 phase, which can be further enhanced in combination with cisplatin (2.5 μM), involving the higher induction of TAp73β, PUMA, NOXA, cleaved caspase-3, and cleaved PARP as compared with a single-agent treatment.
In vivo
MLN8237 significantly reduces the tumor burden with tumor growth inhibition (TGI) of 42% and 80% at 15 mg/kg and 30 mg/kg, respectively, and prolongs the survival of mice compared with the control.
Description
Alisertib (MLN8237, 1028486-01-2) is a highly selective and potent (IC50?= 1 nM) cell permeable inhibitor of Aurora A with off-target binding at GABAA?(IC50?= 490 nM).1?It disrupts the Aurora A-Myc complex leading to Myc degradation2?in Myc amplified neuroblastomas3?and p53-mutant human hepatocellular carcinoma cell4. Alisertib has been found to induce apoptosis and autophagy in breast cancer5?and melanoma6?cells?via?suppression of activation of the p38 MAPK pathway.
Chemical Properties
Off-White Solid
Uses
An Aurora kinase inhibitor, used to treat patients with advanced solid tumors.
Definition
ChEBI: 4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid is a benzazepine.
target
Aurora A
References
1) Sells?et al.?(2015),?MLN8054 and Alisertib (MLN8237):Discovery of Selective Oral Aurora A Inhibitors; ACS Med. Chem. Lett.?6?630 2) Richards?et al.?(2016),?Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors; Proc. Natl. Acad. Sci. USA?113?13726 3) Brockmann?et al.?(2013),?Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma; Cancer Cell?24?75 4) Dauch?et al.?(2016),?A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer; Nat. Med.?22?744 5) Li?et al.?(2015),?The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells; Drug Des. Devel. Ther.?16?1627 6) Shang?et al.?(2017),?Alisertib promotes apoptosis and autophagy in melanoma through p38 MAPK-mediated aurora a signaling; Oncotarget?8?107076
MLN-8237 Preparation Products And Raw materials
Raw materials
Preparation Products
MLN-8237 Suppliers
- Tel
- --
- Fax
- --
- @pharmaffiliates.com
- Country
- India
- ProdList
- 6754
- Advantage
- 58
- Tel
- --
- Fax
- --
- mktg@pharmaffiliates.com
- Country
- India
- ProdList
- 6739
- Advantage
- 58
- Tel
- --
- Fax
- --
- sales@ajchem.in
- Country
- India
- ProdList
- 6100
- Advantage
- 58
View Lastest Price from MLN-8237 manufacturers
- Product
- MLN8237 ;Alisertib 1028486-01-2
- Price
- US $0.00-0.00/g
- Min. Order
- 1g
- Purity
- 98%
- Supply Ability
- 100kgs
- Release date
- 2021-05-23
- Product
- MLN-8237 1028486-01-2
- Price
- US $1.00/KG
- Min. Order
- 1G
- Purity
- 98%
- Supply Ability
- 100KG
- Release date
- 2018-08-21